摘要
目的 对比分析利司那肽联合基础胰岛素与餐时-基础胰岛素治疗2型糖尿病疗效。方法 选取2021年1月—2022年12月台山市人民医院收治的80例2型糖尿病患者为研究对象,按照随机数表法分为两组,各40例。对照组治疗方案为餐时-基础胰岛素(门冬胰岛素+甘精胰岛素),观察组治疗方案为利司那肽+基础胰岛素(甘精胰岛素)。比较两组治疗效果。结果 观察组治疗总有效率(97.50%)高于对照组(82.50%),差异有统计学意义(P<0.05)。治疗前,两组血糖指标对比,差异无统计学意义(P>0.05);治疗后,两组空腹血糖、餐后血糖、糖化血红蛋白水平均明显降低,且观察组降低幅度大于对照组,差异有统计学意义(P<0.05);治疗前,两组各项胰岛功能指标对比,差异无统计学意义(P>0.05);治疗后,两组空腹胰岛素水平、空腹C肽均明显升高,且观察组升高幅度大于对照组,差异有统计学意义(P<0.05)。结论 利司那肽+基础胰岛素是2型糖尿病优质的联合治疗方案,可有效控制血糖,改善胰岛功能。
Objective To compare and analyze the efficacy of lixisenatide combined with basal insulin and mealtime-basal insulin in the treatment of type 2 diabetes mellitus.Methods A total of 80 patients with type 2 diabetes mellitus admitted to Taishan People's Hospital from January 2021 to December 2022 were selected as the research objects and divided into two groups according to the random number table method,with 40 cases in each group.The treatment scheme of the control group was meal time basic insulin(Insulin aspart+Insulin glargine),and the treatment scheme of the observation group was linatide+basic insulin(Insulin glargine).Compared the treatment effects between the two groups.Results The total effective rate of the observation group(97.50%)was higher than that of the control group(82.50%),the difference was statistically significant(P<0.05).Before treatment,there was no statistically significant difference in blood glucose indicators between the two groups(P>0.05);after treatment,the levels of fasting glucose,postprandial glucose and HbA1c in the two groups were significantly reduced,and the reduction in the observation group was greater than that in the control group,the difference was statistically significant(P<0.05);before treatment,there was no statistically significant difference in various pancreatic islet function indicators between the two groups(P>0.05);after treatment,the fasting insulin levels and fasting C-peptide levels in both groups were significantly increased,and the increase in the observation group was greater than that in the control group,the difference was statistically significant(P<0.05).Conclusion Lixisenatide+basal insulin is a high-quality combined treatment program for type 2 diabetes mellitus,which can effectively control blood glucose and improve pancreatic islet function.
作者
黎坚健
陈燕霞
邝德志
LI Jianjian;CHEN Yanxia;KUANG Dezhi(Department of Endocrinology,Taishan People's Hospital,Taishan,Guangdong Province,529200 China)
出处
《糖尿病新世界》
2023年第13期14-17,共4页
Diabetes New World Magazine
